Baseline Characteristics of the Overall Population, and Patients With at Least 1 CDI, LCI, or LCNI, Who Also Had at Least 1 ACVE Within the Observation Period (SCCS Populations), Valencia Region, 2011–2018
| Characteristic . | Overall (n = 2 230 015) . | CDI (n = 1577) . | LCI (n = 625) . | LCNI (n = 1654) . |
|---|---|---|---|---|
| Sex, No. (%) | ||||
| Male | 1 047 415 (47) | 1050 (67) | 403 (64) | 1083 (65) |
| Female | 1 182 600 (53) | 527 (33) | 222 (36) | 571 (35) |
| Age, y | ||||
| Mean (SD) | 62 (12) | 64 (10) | 70 (10) | 70 (10) |
| Median (IQR) | 59 (50–70) | 63 (55–71) | 71 (63–77) | 72 (63–78) |
| Range | 50–111 | 50–93 | 50–95 | 50–95 |
| Comorbidities, No. (%) | ||||
| DM | 473 589 (21) | 807 (51) | 400 (64) | 998 (60) |
| COPD | 182 297 (8.2) | 299 (19) | 252 (40) | 713 (43) |
| Liver disease | 125 561 (5.6) | 177 (11) | 68 (11) | 234 (14) |
| Kidney disease | 205 565 (9.2) | 376 (24) | 290 (46) | 852 (52) |
| Obesity | 278 701 (12) | 458 (29) | 177 (28) | 434 (26) |
| Chronic CVD | 1 200 873 (54) | 1389 (88) | 602 (96) | 1572 (95) |
| Immunodeficiency | 484 688 (22) | 465 (29) | 241 (38) | 652 (39) |
| Number of comorbidities, No. (%) | ||||
| 0 | 701 108 (31) | 56 (4) | 5 (1) | 15 (0.9) |
| 1 | 545 313 (25) | 289 (18) | 33 (5) | 96 (5.8) |
| 2 | 438 425 (20) | 378 (24) | 112 (18) | 276 (16.7) |
| 3 | 292 476 (13) | 364 (23) | 136 (22) | 394 (23.8) |
| 4 | 158 259 (7) | 250 (16) | 171 (27) | 376 (22.7) |
| >5 | 94 434 (4) | 240 (15) | 168 (27) | 497 (30.1) |
| Death, No. (%) | 309 708 (14) | 277 (18) | 270 (43) | 854 (52) |
| Number of ACVE, No. (%) | ||||
| 0 | 2 189 680 (98) | … | … | … |
| 1 | 36 317 (1.6) | 1425 (90.3) | 474 (75.8) | 1287 (77.8) |
| 2 | 3384 (0.2) | 132 (8.4) | 117 (18.7) | 299 (18) |
| 3 | 505 (<0.1) | 17 (1.1) | 26 (4.2) | 49 (3.0) |
| >4 | 129 (<0.1) | 3 (0.2) | 8 (1.3) | 19 (1.2) |
| Characteristic . | Overall (n = 2 230 015) . | CDI (n = 1577) . | LCI (n = 625) . | LCNI (n = 1654) . |
|---|---|---|---|---|
| Sex, No. (%) | ||||
| Male | 1 047 415 (47) | 1050 (67) | 403 (64) | 1083 (65) |
| Female | 1 182 600 (53) | 527 (33) | 222 (36) | 571 (35) |
| Age, y | ||||
| Mean (SD) | 62 (12) | 64 (10) | 70 (10) | 70 (10) |
| Median (IQR) | 59 (50–70) | 63 (55–71) | 71 (63–77) | 72 (63–78) |
| Range | 50–111 | 50–93 | 50–95 | 50–95 |
| Comorbidities, No. (%) | ||||
| DM | 473 589 (21) | 807 (51) | 400 (64) | 998 (60) |
| COPD | 182 297 (8.2) | 299 (19) | 252 (40) | 713 (43) |
| Liver disease | 125 561 (5.6) | 177 (11) | 68 (11) | 234 (14) |
| Kidney disease | 205 565 (9.2) | 376 (24) | 290 (46) | 852 (52) |
| Obesity | 278 701 (12) | 458 (29) | 177 (28) | 434 (26) |
| Chronic CVD | 1 200 873 (54) | 1389 (88) | 602 (96) | 1572 (95) |
| Immunodeficiency | 484 688 (22) | 465 (29) | 241 (38) | 652 (39) |
| Number of comorbidities, No. (%) | ||||
| 0 | 701 108 (31) | 56 (4) | 5 (1) | 15 (0.9) |
| 1 | 545 313 (25) | 289 (18) | 33 (5) | 96 (5.8) |
| 2 | 438 425 (20) | 378 (24) | 112 (18) | 276 (16.7) |
| 3 | 292 476 (13) | 364 (23) | 136 (22) | 394 (23.8) |
| 4 | 158 259 (7) | 250 (16) | 171 (27) | 376 (22.7) |
| >5 | 94 434 (4) | 240 (15) | 168 (27) | 497 (30.1) |
| Death, No. (%) | 309 708 (14) | 277 (18) | 270 (43) | 854 (52) |
| Number of ACVE, No. (%) | ||||
| 0 | 2 189 680 (98) | … | … | … |
| 1 | 36 317 (1.6) | 1425 (90.3) | 474 (75.8) | 1287 (77.8) |
| 2 | 3384 (0.2) | 132 (8.4) | 117 (18.7) | 299 (18) |
| 3 | 505 (<0.1) | 17 (1.1) | 26 (4.2) | 49 (3.0) |
| >4 | 129 (<0.1) | 3 (0.2) | 8 (1.3) | 19 (1.2) |
Abbreviations: ACVE, acute cardiovascular event; CDI, clinically diagnosed influenza; CVD, cardiovascular disease; DM, diabetes mellitus; IQR, interquartile range; LCI, laboratory-confirmed influenza; LCNI, laboratory-confirmed negative for influenza; SCCS, self-controlled case series.
Baseline Characteristics of the Overall Population, and Patients With at Least 1 CDI, LCI, or LCNI, Who Also Had at Least 1 ACVE Within the Observation Period (SCCS Populations), Valencia Region, 2011–2018
| Characteristic . | Overall (n = 2 230 015) . | CDI (n = 1577) . | LCI (n = 625) . | LCNI (n = 1654) . |
|---|---|---|---|---|
| Sex, No. (%) | ||||
| Male | 1 047 415 (47) | 1050 (67) | 403 (64) | 1083 (65) |
| Female | 1 182 600 (53) | 527 (33) | 222 (36) | 571 (35) |
| Age, y | ||||
| Mean (SD) | 62 (12) | 64 (10) | 70 (10) | 70 (10) |
| Median (IQR) | 59 (50–70) | 63 (55–71) | 71 (63–77) | 72 (63–78) |
| Range | 50–111 | 50–93 | 50–95 | 50–95 |
| Comorbidities, No. (%) | ||||
| DM | 473 589 (21) | 807 (51) | 400 (64) | 998 (60) |
| COPD | 182 297 (8.2) | 299 (19) | 252 (40) | 713 (43) |
| Liver disease | 125 561 (5.6) | 177 (11) | 68 (11) | 234 (14) |
| Kidney disease | 205 565 (9.2) | 376 (24) | 290 (46) | 852 (52) |
| Obesity | 278 701 (12) | 458 (29) | 177 (28) | 434 (26) |
| Chronic CVD | 1 200 873 (54) | 1389 (88) | 602 (96) | 1572 (95) |
| Immunodeficiency | 484 688 (22) | 465 (29) | 241 (38) | 652 (39) |
| Number of comorbidities, No. (%) | ||||
| 0 | 701 108 (31) | 56 (4) | 5 (1) | 15 (0.9) |
| 1 | 545 313 (25) | 289 (18) | 33 (5) | 96 (5.8) |
| 2 | 438 425 (20) | 378 (24) | 112 (18) | 276 (16.7) |
| 3 | 292 476 (13) | 364 (23) | 136 (22) | 394 (23.8) |
| 4 | 158 259 (7) | 250 (16) | 171 (27) | 376 (22.7) |
| >5 | 94 434 (4) | 240 (15) | 168 (27) | 497 (30.1) |
| Death, No. (%) | 309 708 (14) | 277 (18) | 270 (43) | 854 (52) |
| Number of ACVE, No. (%) | ||||
| 0 | 2 189 680 (98) | … | … | … |
| 1 | 36 317 (1.6) | 1425 (90.3) | 474 (75.8) | 1287 (77.8) |
| 2 | 3384 (0.2) | 132 (8.4) | 117 (18.7) | 299 (18) |
| 3 | 505 (<0.1) | 17 (1.1) | 26 (4.2) | 49 (3.0) |
| >4 | 129 (<0.1) | 3 (0.2) | 8 (1.3) | 19 (1.2) |
| Characteristic . | Overall (n = 2 230 015) . | CDI (n = 1577) . | LCI (n = 625) . | LCNI (n = 1654) . |
|---|---|---|---|---|
| Sex, No. (%) | ||||
| Male | 1 047 415 (47) | 1050 (67) | 403 (64) | 1083 (65) |
| Female | 1 182 600 (53) | 527 (33) | 222 (36) | 571 (35) |
| Age, y | ||||
| Mean (SD) | 62 (12) | 64 (10) | 70 (10) | 70 (10) |
| Median (IQR) | 59 (50–70) | 63 (55–71) | 71 (63–77) | 72 (63–78) |
| Range | 50–111 | 50–93 | 50–95 | 50–95 |
| Comorbidities, No. (%) | ||||
| DM | 473 589 (21) | 807 (51) | 400 (64) | 998 (60) |
| COPD | 182 297 (8.2) | 299 (19) | 252 (40) | 713 (43) |
| Liver disease | 125 561 (5.6) | 177 (11) | 68 (11) | 234 (14) |
| Kidney disease | 205 565 (9.2) | 376 (24) | 290 (46) | 852 (52) |
| Obesity | 278 701 (12) | 458 (29) | 177 (28) | 434 (26) |
| Chronic CVD | 1 200 873 (54) | 1389 (88) | 602 (96) | 1572 (95) |
| Immunodeficiency | 484 688 (22) | 465 (29) | 241 (38) | 652 (39) |
| Number of comorbidities, No. (%) | ||||
| 0 | 701 108 (31) | 56 (4) | 5 (1) | 15 (0.9) |
| 1 | 545 313 (25) | 289 (18) | 33 (5) | 96 (5.8) |
| 2 | 438 425 (20) | 378 (24) | 112 (18) | 276 (16.7) |
| 3 | 292 476 (13) | 364 (23) | 136 (22) | 394 (23.8) |
| 4 | 158 259 (7) | 250 (16) | 171 (27) | 376 (22.7) |
| >5 | 94 434 (4) | 240 (15) | 168 (27) | 497 (30.1) |
| Death, No. (%) | 309 708 (14) | 277 (18) | 270 (43) | 854 (52) |
| Number of ACVE, No. (%) | ||||
| 0 | 2 189 680 (98) | … | … | … |
| 1 | 36 317 (1.6) | 1425 (90.3) | 474 (75.8) | 1287 (77.8) |
| 2 | 3384 (0.2) | 132 (8.4) | 117 (18.7) | 299 (18) |
| 3 | 505 (<0.1) | 17 (1.1) | 26 (4.2) | 49 (3.0) |
| >4 | 129 (<0.1) | 3 (0.2) | 8 (1.3) | 19 (1.2) |
Abbreviations: ACVE, acute cardiovascular event; CDI, clinically diagnosed influenza; CVD, cardiovascular disease; DM, diabetes mellitus; IQR, interquartile range; LCI, laboratory-confirmed influenza; LCNI, laboratory-confirmed negative for influenza; SCCS, self-controlled case series.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
